Bharat Parenterals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY23Mar 2023
+2.8%
−24.1%
−27.8%
+14.2%
+13.6%
+41.3%
+15.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BPLPHARMA₹1,912.60

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹1,105 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Revenue Growth—+2.8
EBITDA Growth—-24.1
EBIT Growth—-27.8
Net Income Growth—+14.2
EPS Growth—+13.6
Total Assets Growth—+41.3
Total Equity Growth—+15.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.